Metastatic breast cancer treated with lapatinib with a prolonged benefit: a case report and a review of therapeutic options available.
A 53-year-old woman was treated, after trastuzumab progression of HER2-positive metastatic disease, with capecitabine plus lapatinib and subsequently with lapatinib alone. To date, she has had persistent remission of disease since 2009.